Therapeutic Solutions International (TSOI) 10-Q 16 May 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2023	May 15, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	000-54554
Entity Registrant Name	Therapeutic Solutions International, Inc.
Entity Central Index Key	0001419051
Entity Tax Identification Number	45-1226465
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	701 Wild Rose Lane
Entity Address, City or Town	Elk City
Entity Address, State or Province	ID
Entity Address, Postal Zip Code	83525
City Area Code	(760)
Local Phone Number	295-7208
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		3,021,589,908

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 18,531	$ 18,040
Restricted cash	11,003	11,003
Accounts receivable	17,726	25,398
Inventory	35,685	42,428
Prepaid expenses and other current assets	117,506	212,352
Total current assets	200,451	309,221
Property and equipment, net	270,358	273,078
Right-of-use asset	144,226	8,612
Other assets	2,934,774	3,014,620
Total assets	3,549,809	3,605,531
Current liabilities:
Accrued expenses and other current liabilities	544,913	531,783
Lease liability	24,119	8,612
Convertible notes payable, net of discount of $146,464 and $175,063, at March 31, 2023 and December 31, 2022, respectively	60,536	65,187
Derivative liabilities	227,077	202,144
Total current liabilities	2,255,355	2,210,237
LONG TERM LIABILITIES
Notes payable, net of current portion	9,296	10,507
Lease liability, net of current portion	120,107
TOTAL LIABILITIES	2,384,758	2,220,744
Commitments and contingencies
Shareholders' Equity (Deficit):
Preferred stock, $0.001 par value; 5,000,000 shares authorized, 2 shares and 2 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively
Common stock, $0.001 par value; 4,500,000,000 shares authorized; 2,748,956,631 and 2,617,390,830 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively.	2,748,958	2,617,392
Additional paid-in capital	16,677,708	16,334,129
Shares to be issued	9,324	126,324
Subscription receivable	(21,000)	(21,000)
Accumulated deficit	(18,249,939)	(17,672,058)
Total shareholders' equity (deficit)	1,165,051	1,384,787
Total liabilities and shareholders' equity (deficit)	3,549,809	3,605,531
Nonrelated Party [Member]
Current liabilities:
Accounts payable	391,712	401,992
Notes payable	4,638	4,638
Related Party [Member]
Current liabilities:
Accounts payable	7,217	7,209
Notes payable	$ 995,143	$ 988,672

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Debt instrument, unamortized discount, current	$ 146,464	$ 175,063
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	2	2
Preferred stock, shares outstanding	2	2
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	4,500,000,000	4,500,000,000
Common stock, shares, issued	2,748,956,631	2,617,390,830
Common stock, shares, outstanding	2,748,956,631	2,617,390,830

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Net sales	$ 23,123	$ 84,898
Cost of goods sold	8,466	15,938
Gross profit	14,657	68,960
Operating expenses:
General and administrative	119,401	40,007
Salaries, wages, and related costs	110,525	114,285
Consulting fees	69,284	87,116
Legal and professional fees	92,587	50,092
Research and development	52,727	304,159
Total operating expenses	444,524	595,659
Loss from operations	(429,867)	(526,699)
Other income (expense):
Loss on derivative liabilities	18,134	(66,532)
Change in fair value of derivative liabilities	(44,336)	142,306
Interest expense	(121,812)	(149,998)
Total other income (expense)	(148,014)	(74,224)
LOSS BEFORE PROVISION FOR INCOME TAXES	(577,881)	(600,923)
Provision for income taxes
Net loss	$ (577,881)	$ (600,923)
Net loss per share - basic and diluted	$ 0	$ 0
Weighted average shares outstanding - basic and diluted	2,692,056,744	2,393,701,868

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) (Unaudited) - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Shares To Be Issued [Member]	Subscription Receivable [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021		$ 2,311,125	$ 10,899,139		$ (21,000)	$ (13,994,246)	$ (804,982)
Balance, shares at Dec. 31, 2021		2,311,123,860
Common stock issued for salaries		$ 1,034	28,965				29,999
Common stock issued for salaries, shares		1,034,482
Common stock issued for cash		$ 44,500	400,500		(100,000)		345,000
Common stock issued for cash, shares		44,500,000
Common stock issued for license		$ 149,402	2,958,168				3,107,570
Common stock issued for license, shares		149,402,390
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		$ 8,937	219,428				228,365
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares		8,937,448
Net loss						(600,923)	(600,923)
Balance at Mar. 31, 2022		$ 2,514,998	14,506,200		(121,000)	(14,595,169)	2,305,029
Balance, shares at Mar. 31, 2022		2,514,998,180
Balance at Dec. 31, 2021		$ 2,311,125	10,899,139		(21,000)	(13,994,246)	(804,982)
Balance, shares at Dec. 31, 2021		2,311,123,860
Balance at Dec. 31, 2022		$ 2,617,392	16,334,129	126,324	(21,000)	(17,672,058)	1,384,787
Balance, shares at Dec. 31, 2022	2	2,617,390,830
Common stock issued for salaries		$ 4,082	15,918				20,000
Common stock issued for salaries, shares		4,081,632
Common stock issued for cash		$ 60,225	69,861				130,086
Common stock issued for cash, shares		60,224,825
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		$ 46,259	157,200	(15,000)			188,459
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares		46,259,344
Net loss						(577,881)	(577,881)
Common stock issued for services		$ 21,000	100,600	(102,000)			19,600
Common stock issued for services, shares		21,000,000
Balance at Mar. 31, 2023		$ 2,748,958	$ 16,677,708	$ 9,324	$ (21,000)	$ (18,249,939)	$ 1,165,051
Balance, shares at Mar. 31, 2023	2	2,748,956,631

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities
Net loss	$ (577,881)	$ (600,923)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation to related parties	19,600
Loss on derivative liabilities	(18,134)	66,532
Change in fair value of derivative liabilities	44,336	(142,306)
Amortization of prepaid stock-based compensation	60,943	303,056
Amortization of debt discount	106,664	134,031
Patent amortization	74,194	5,693
Depreciation	2,720	1,163
Changes in operating assets and liabilities:
Accounts receivable	7,672	(19,721)
Inventory	6,743	383
Prepaid expenses and other current assets	37,605	17,021
Right-of-use asset	10,630	6,261
Accounts payable	(10,283)	(21,586)
Accounts payable - related parties	8	(2,451)
Accrued expenses and other current liabilities	44,735	44,243
Lease liability	(10,630)	(6,261)
Net cash used in operating activities	(201,078)	(214,865)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of license		(200,000)
Issuance of note receivable	1,951
Net cash used in investing activities	1,951	(200,000)
Cash flows from financing activities
Payments on notes payable to related party	(8)	(2,404)
Proceeds from convertible notes payable	70,750	145,000
Payments on notes payable	(1,210)	(1,077)
Proceeds from sale of common stock	130,086	345,000
Net cash provided by financing activities	199,618	486,519
Net increase (decrease) in cash, cash equivalents and restricted cash	491	71,654
Cash, cash equivalents and restricted cash at beginning of period	29,043	104,259
Cash, cash equivalents and restricted cash at end of period	29,534	175,913
Supplemental cash flow information:
Cash paid for interest	663	710
Cash paid for income taxes
Non-cash investing and financing transactions:
Original issuance discount on convertible notes payable	8,500	11,250
Debt discount recorded in connection with derivative liability	69,565	145,000
Common stock issued in conversion of convertible notes payable and interest	188,459	228,365
Common stock issued for accrued salaries	20,000	29,999
Accrued interest added to principal	6,479	6,478
Common stock issued for license	146,244	3,107,570
Common stock issued for subscription receivable		100,000
Right of use asset and lease liability	146,244
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:
Cash and cash equivalents	18,531	165,690
Restricted cash	11,003	10,223
Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows:	$ 29,534	$ 175,913

Organization and Business Descr

Organization and Business Description	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Description	Note 1 – Organization and Business Description Therapeutic Solutions International, Inc. (“TSI” or the “Company”) was organized August 6, 2007 Business Description Currently the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions. TSOI is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury, and for daily health. Nutraceutical Division Cellular Division The stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability. Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment to enhance receptivity of regenerative cells such as stem cells. On March 4, 2021, the Company received an IND Serial # 27377 for a clinical trial of 10 patients with CTE. On August 4th, 2021, the Company announced clearance from the Food and Drug Administration (FDA) to initiate a Phase III pivotal trial for registration of the Company’s JadiCell™ universal donor stem cell as a treatment for COVID-19 associated lung failure under IND # 19757. In previous studies the Company has demonstrated the superior activity of JadiCell to other types of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, the JadiCell was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%. In addition, the Company has filed data with the FDA, as part of IND #17448, which demonstrated that treatment of cancer patients with StemVacs™ resulted in enhanced activity of a type of immunological cell called “natural killer” cells, otherwise known as “NK cells.” The Company has also developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body’s NK cells. Most recently the Company announced filing of a patent application covering the use stem cell derived exosomes for treatment of aortic aneurysms. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 Management does not expect existing cash as of March 31, 2023, to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these financial statements. These financial statements have been prepared on a going concern basis which assumed the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of March 31, 2023, the Company has incurred losses totaling $ 18.2

Basis of presentation and signi

Basis of presentation and significant accounting policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of presentation and significant accounting policies	Note 2 – Basis of presentation and significant accounting policies Basis of Presentation The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented. Revenue Recognition The Company recognizes revenue in accordance with ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) Identify the contract with a customer. 2) Identify the performance obligations in the contract. 3) Determine the transaction price. 4) Allocate the transaction price to the performance obligations in the contract. 5) Recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service. Returns. Wholesale policies: Delivery. Purchase Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 Inspection of Goods & Rejection. Risk of Loss. Retail policies of e-commerce: Shipping. Out of Stock. Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $ 250,000 0 0 Inventories Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items. Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2022 and 2021, as disclosed in Note 8 containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $ 227,077 202,144 Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of March 31, 2023 and December 31, 2022, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the three months ended March 31, 2023: Schedule of Change in Derivative Liability Balance, December 31, 2022 $ 202,144 Issuance of new derivative liabilities 77,856 Conversions (97,259 ) Change in fair market value of derivative liabilities 44,336 Balance, March 31, 2023 $ 227,077 Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates. Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss. Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of March 31, 2023 and 2022, a total of 372,997,016 134,887,029 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Depreciation expense for the three months ended March 31, 2023 and 2022 was $ 2,720 1,163 Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the three months ended March 31, 2023 and 2022 was $ 74,194 5,693 Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $ 52,727 304,159 Income Taxes The Company accounts for income taxes under ASC 740 “Income Taxes,” “Accounting for Income Taxes” “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares. Leases On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $ 144,226

Restricted cash

Restricted cash	3 Months Ended
	Mar. 31, 2023
Cash and Cash Equivalents [Abstract]
Restricted cash	Note 3 – Restricted cash Included in current assets is a $ 10,000 0.6 This certificate matures on June 17, 2023, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011.

Prepaid expense and other curre

Prepaid expense and other current assets	3 Months Ended
	Mar. 31, 2023
Prepaid Expense And Other Current Assets
Prepaid expense and other current assets	Note 4 – Prepaid expense and other current assets Prepaid expenses and other current assets consist of the following: Schedule of Prepaid Expenses and Other Current Assets March 31, 2023 December 31, 2022 Prepaid consulting $ 84,918 $ 148,550 Insurance 856 1,141 Prepaid costs 31,732 62,661 Total $ 117,506 $ 212,352 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023

Fixed assets

Fixed assets	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Fixed assets	Note 5 – Fixed assets Fixed assets consist of the following: Schedule of Fixed Assets March 31, 2023 December 31, 2022 Land $ 235,223 $ 235,223 Vehicles 50,514 50,514 Computer hardware 6,135 6,135 Office furniture and equipment 7,912 7,912 Shipping and other equipment 1,575 1,575 Total 301,359 301,359 Accumulated depreciation (31,001 ) (28,281 ) Property and equipment, net $ 270,358 $ 273,078 Depreciation expense was $ 2,720 1,163

Other assets

Other assets	3 Months Ended
	Mar. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other assets	Note 6 – Other assets Other assets consist of the following: Schedule of Other Assets March 31, 2023 December 31, 2022 Prepaid consulting $ 1,884 $ 7,537 Deposit 4,123 4,123 Licenses, net 2,928,767 3,002,960 Total $ 2,934,774 $ 3,014,620 As of June 1, 2019, we entered into a license agreement, which will be amortized over the life of the Patent. The Patent expires December 31, 2032. The Exclusive Patent License to the Jadi Cell is for use under the designated areas of CTE (Chronic Traumatic Encephalopathy), and TBI (Traumatic Brain Injury). The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived from US Patent No.: 9,803,176 B2. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following: Schedule of Net Licenses March 31, 2023 December 31, 2022 Licenses $ 3,261,122 $ 3,261,122 Accumulated amortization (332,355 ) (258,162 ) Licenses, net $ 2,928,767 $ 3,002,960 Amortization expense for the three months ended March 31, 2023 and 2022 was $ 74,194 5,693

Notes Payable-Related Party

Notes Payable-Related Party	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Notes Payable-Related Party	Note 7 - Notes Payable-Related Party At March 31, 2023 and December 31, 2022, the Company has unsecured interest-bearing demand notes outstanding to certain officers and directors amounting to $ 995,143 988,672 12,956 12,956 251,000 0.004 0.005

Convertible Notes Payable

Convertible Notes Payable	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 8 – Convertible Notes Payable At various times during the three months ended March 31, 2023, the Company entered into convertible promissory notes with principal amounts totaling $ 79,250 70,750 8,500 10 mature on dates ranging from September 27, 2023 to February 8, 2024. The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. 372,997,016 Derivative liabilities These convertible promissory notes are convertible into a variable number of shares of common stock for which there is not a floor to the number of common stock we might be required to issue. Based on the requirements of ASC 815 Derivatives and Hedging, the conversion feature represented an embedded derivative that is required to be bifurcated and accounted for as a separate derivative liability. The derivative liability is originally recorded at its estimated fair value and is required to be revalued at each conversion event and reporting period. Changes in the derivative liability fair value are reported in operating results each reporting period. For the notes issued during the three months ended March 31, 2023, the Company valued the conversion feature on the date of issuance resulting in an initial liability of $ 77,856 8,291 0.0033 0.0034 0.0049 0.006 0 124 127 4.74 4.87 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 During the three months ended March 31, 2023, convertible notes with principal and accrued interest balances totaling $ 117,625 46,259,344 26,425 0.0017 0.004 0.003 0.006 0 110 164 4.55 4.88 0.48 0.50 On March 31, 2023, the derivative liabilities on the remaining convertible notes were revalued at $ 227,077 44,336 0.0016 0.0027 0 140 166 4.64 0.49 0.86 The Company amortizes the discounts over the term of the convertible promissory notes using the straight-line method which is similar to the effective interest method. During the three months ended March 31, 2023 and 2022, the Company amortized $ 106,664 134,031 146,464

Equity

Equity	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Equity	Note 9 – Equity Our authorized capital stock consists of an aggregate of 4,505,000,000 4,500,000,000 0.001 5,000,000 2,748,956,631 2 In 2022, we issued 44,500,000 445,000 In 2022, we issued 32,412,577 691,520 In 2022, we committed to issue 3,000,000 18,000 In 2022, we issued 4,812,259 67,399 In 2022, we issued 149,402,390 3,107,570 In 2022, we issued 11,000,000 242,320 In 2022, we issued 64,139,744 1,313,772 In 2022, we committed to issue 4,054,054 15,000 In 2023, we issued 60,224,825 130,086 In 2023, we issued 21,000,000 141,200 In 2023, we issued 4,081,632 20,000 In 2023, we issued 46,259,344 203,459 On August 4, 2022, the Board of Directors designated “Series A Preferred Stock” and caused to be filed a Certificate of Designation pursuant to NRS 78.1955 with the State of Nevada, and upon approval the Board has issued One (1) share of Series A Preferred Stock to Thomas E. Ichim, and One (1) share of Series A Preferred Stock to Timothy G. Dixon. The Holder of the Series A Preferred Stock shall be entitled to vote on all matters subject to a vote or written consent of the holders of the Corporation’s Common Stock, and on all such matters, the share of Series A Preferred Stock shall be entitled to that number of votes equal to the number of votes that all issued and outstanding shares of Common Stock and all other securities of the Corporation are entitled to, as of any such date of determination, on a fully diluted basis, plus One Million (1,000,000) votes, it being the intention that the Holder(s) of the Series A Preferred Stock shall have effective voting control of the Corporation, on a fully diluted basis. The Holder(s) of the Series A Preferred Stock shall vote together with the holders of Common Stock as a single class. On August 9, 2022, we issued 2 0.001 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023

Subsequent events

Subsequent events	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent events	Note 10 – Subsequent events On April 3, 2023, we issued 21,308,333 31,962 On April 6, 2023, we issued 40,959,979 75,366 On April 20, 2023, we issued 25,000,000 0024 On April 24, 2023, we issued 89,639,965 150,595 On April 28, 2023, we issued 20,000,000 30,000 On May 3, 2023, we issued 17,975,000 26,963 On May 10, 2023, we issued 16,500,000 82,500 On May 10, 2023, we issued 27,500,000 110,000 On May 3, 2023, we issued 13,750,000 27,500 In accordance with ASC 855, the Company has analyzed its operations subsequent to November 17, 2022 through the date these financial statements were issued, and has determined that it does not have any other material subsequent events to disclose in these financial statements.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 11 – Commitments and Contingencies Effective March 22, 2023, the Company entered into a sixth amendment to a Lease Agreement for property located in Oceanside, CA. The lease consists of approximately 1,700 60 April 30, 2028 6,261 6,261 The lease will expire in 2028. The weighted average discount rate used for this lease is 5

Basis of presentation and sig_2

Basis of presentation and significant accounting policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) Identify the contract with a customer. 2) Identify the performance obligations in the contract. 3) Determine the transaction price. 4) Allocate the transaction price to the performance obligations in the contract. 5) Recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service. Returns. Wholesale policies: Delivery. Purchase Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 Inspection of Goods & Rejection. Risk of Loss. Retail policies of e-commerce: Shipping. Out of Stock.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $ 250,000 0 0
Inventories	Inventories Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials and assembly items.
Derivative Liabilities	Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2022 and 2021, as disclosed in Note 8 containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023 Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $ 227,077 202,144
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of March 31, 2023 and December 31, 2022, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the three months ended March 31, 2023: Schedule of Change in Derivative Liability Balance, December 31, 2022 $ 202,144 Issuance of new derivative liabilities 77,856 Conversions (97,259 ) Change in fair market value of derivative liabilities 44,336 Balance, March 31, 2023 $ 227,077
Use of Estimates	Use of Estimates Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates.
Comprehensive Loss	Comprehensive Loss Comprehensive loss for the periods reported was comprised solely of the Company’s net loss.
Net Loss Per Share	Net Loss Per Share Basic loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive. As of March 31, 2023 and 2022, a total of 372,997,016 134,887,029 THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2023
Depreciation and Amortization	Depreciation and Amortization Depreciation is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight line method over the term of the agreement. Depreciation expense for the three months ended March 31, 2023 and 2022 was $ 2,720 1,163
Intangible Assets	Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the three months ended March 31, 2023 and 2022 was $ 74,194 5,693
Long-lived Assets	Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value.
Research and Development	Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $ 52,727 304,159
Income Taxes	Income Taxes The Company accounts for income taxes under ASC 740 “Income Taxes,” “Accounting for Income Taxes” “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.”
Stock-Based Compensation	Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted and nonrefundable shares.
Leases	Leases On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company recorded a Right-of-use asset and a Lease Liability of $ 144,226

Basis of presentation and sig_3

Basis of presentation and significant accounting policies (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Schedule of Change in Derivative Liability	The following is the change in derivative liability for the three months ended March 31, 2023: Schedule of Change in Derivative Liability Balance, December 31, 2022 $ 202,144 Issuance of new derivative liabilities 77,856 Conversions (97,259 ) Change in fair market value of derivative liabilities 44,336 Balance, March 31, 2023 $ 227,077

Prepaid expense and other cur_2

Prepaid expense and other current assets (Tables)	3 Months Ended
	Mar. 31, 2023
Prepaid Expense And Other Current Assets
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following: Schedule of Prepaid Expenses and Other Current Assets March 31, 2023 December 31, 2022 Prepaid consulting $ 84,918 $ 148,550 Insurance 856 1,141 Prepaid costs 31,732 62,661 Total $ 117,506 $ 212,352

Fixed assets (Tables)

Fixed assets (Tables)	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following: Schedule of Fixed Assets March 31, 2023 December 31, 2022 Land $ 235,223 $ 235,223 Vehicles 50,514 50,514 Computer hardware 6,135 6,135 Office furniture and equipment 7,912 7,912 Shipping and other equipment 1,575 1,575 Total 301,359 301,359 Accumulated depreciation (31,001 ) (28,281 ) Property and equipment, net $ 270,358 $ 273,078

Other assets (Tables)

Other assets (Tables)	3 Months Ended
	Mar. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Assets	Other assets consist of the following: Schedule of Other Assets March 31, 2023 December 31, 2022 Prepaid consulting $ 1,884 $ 7,537 Deposit 4,123 4,123 Licenses, net 2,928,767 3,002,960 Total $ 2,934,774 $ 3,014,620
Schedule of Net Licenses	Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above consists of the following: Schedule of Net Licenses March 31, 2023 December 31, 2022 Licenses $ 3,261,122 $ 3,261,122 Accumulated amortization (332,355 ) (258,162 ) Licenses, net $ 2,928,767 $ 3,002,960

Organization and Business Des_2

Organization and Business Description (Details Narrative) - USD ($) $ in Millions		3 Months Ended
	Aug. 04, 2021	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Entity incorporation date		Aug. 06, 2007
Unusual or infrequent item, description	the JadiCell was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%.
Net loss		$ 18.2

Schedule of Change in Derivativ

Schedule of Change in Derivative Liability (Details)	3 Months Ended
	Mar. 31, 2023 USD ($)
Accounting Policies [Abstract]
Beginning Balance	$ 202,144
Issuance of new derivative liabilities	77,856
Conversions	(97,259)
Change in fair market value of derivative liabilities	44,336
Ending Balance	$ 227,077

Basis of presentation and sig_4

Basis of presentation and significant accounting policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Accounting Policies [Abstract]
Payments description	Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of $500,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail.
Cash, FDIC insured amount	$ 250,000
Cash, uninsured amount	0		$ 0
Derivative liabilities	$ 227,077		202,144
Antidilutive securities excluded from computation of earnings per share	372,997,016	134,887,029
Depreciation expense	$ 2,720	$ 1,163
Amortization expense of intangible assets	74,194	5,693
Research and development expense	52,727	$ 304,159
Right-of-use asset	144,226		$ 8,612
Lease liability	$ 144,226

Restricted cash (Details Narrat

Restricted cash (Details Narrative)	3 Months Ended
	Mar. 31, 2023 USD ($)
Cash and Cash Equivalents [Abstract]
Certificates of deposits	$ 10,000
Annual interest rate	0.60%
Restricted cash description	This certificate matures on June 17, 2023, and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011.

Schedule of Prepaid Expenses an

Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Prepaid Expense And Other Current Assets
Prepaid consulting	$ 84,918	$ 148,550
Insurance	856	1,141
Prepaid costs	31,732	62,661
Total	$ 117,506	$ 212,352

Schedule of Fixed Assets (Detai

Schedule of Fixed Assets (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Total	$ 301,359	$ 301,359
Accumulated depreciation	(31,001)	(28,281)
Property and equipment, net	270,358	273,078
Land [Member]
Property, Plant and Equipment [Line Items]
Total	235,223	235,223
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Total	50,514	50,514
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	6,135	6,135
Office Furniture And Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	7,912	7,912
Shipping And Other Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	$ 1,575	$ 1,575

Fixed assets (Details Narrative

Fixed assets (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 2,720	$ 1,163

Schedule of Other Assets (Detai

Schedule of Other Assets (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid consulting	$ 1,884	$ 7,537
Deposit	4,123	4,123
Licenses, net	2,928,767	3,002,960
Total	$ 2,934,774	$ 3,014,620

Schedule of Net Licenses (Detai

Schedule of Net Licenses (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Licenses	$ 3,261,122	$ 3,261,122
Accumulated amortization	(332,355)	(258,162)
Licenses, net	$ 2,928,767	$ 3,002,960

Other assets (Details Narrative

Other assets (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Amortization expenses	$ 74,194	$ 5,693

Notes Payable-Related Party (De

Notes Payable-Related Party (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Related Party [Member]
Debt Instrument [Line Items]
Notes payable related party	$ 995,143	$ 988,672
Officers and Directors [Member]
Debt Instrument [Line Items]
Notes payable related party		988,672
Accrued interest	12,956	$ 12,956
Debt conversion amount	$ 251,000
Officers and Directors [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt conversion price	$ 0.004
Officers and Directors [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt conversion price	$ 0.005
Officers and Directors [Member] | Related Party [Member]
Debt Instrument [Line Items]
Notes payable related party	$ 995,143

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative)	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
Proceeds from convertible debt	$ 70,750	$ 145,000
Derivative liabilities	227,077		$ 202,144
Gain loss on derivative liabilities	(44,336)	142,306
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt discount	146,464
Interest expenses	106,664	$ 134,031
Derivative [Member]
Debt Instrument [Line Items]
Derivative issuance liability	77,856
Loss on derivative liability	$ 8,291
Derivative [Member] | Measurement Input, Conversion Price [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.0033
Derivative [Member] | Measurement Input, Conversion Price [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.0034
Derivative [Member] | Measurement Input, Share Price [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.0049
Derivative [Member] | Measurement Input, Share Price [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.006
Derivative [Member] | Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0
Derivative [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	124
Derivative [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	127
Derivative [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	4.74
Derivative [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	4.87
Convertible Promissory Note [Member]
Debt Instrument [Line Items]
Debt principal amount	$ 79,250
Proceeds from convertible debt	70,750
Debt discount	$ 8,500
Interest rate percentage	10%
Debt maturity date description	mature on dates ranging from September 27, 2023 to February 8, 2024.
Debt conversion description	The convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion price per share is equal to 63% of the average of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%.
Common shares reserve for future issuance | shares	372,997,016
Convertible Notes [Member]
Debt Instrument [Line Items]
Debt conversion of convertible shares, value	$ 117,625
Debt conversion of convertible shares | shares	46,259,344
Convertible Notes [Member] | Measurement Input, Conversion Price [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.0017
Convertible Notes [Member] | Measurement Input, Conversion Price [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.004
Convertible Notes [Member] | Measurement Input, Share Price [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.003
Convertible Notes [Member] | Measurement Input, Share Price [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.006
Convertible Notes [Member] | Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0
Convertible Notes [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	110
Convertible Notes [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	164
Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	4.55
Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	4.88
Convertible Notes [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term	5 months 23 days
Convertible Notes [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term	6 months
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Gain on derivative liabilities	$ 26,425
Remaining Convertible Notes [Member]
Debt Instrument [Line Items]
Derivative liabilities	227,077
Gain loss on derivative liabilities	$ 44,336
Remaining Convertible Notes [Member] | Measurement Input, Share Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.0027
Remaining Convertible Notes [Member] | Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	0
Remaining Convertible Notes [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	140
Remaining Convertible Notes [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	166
Remaining Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input	4.64
Remaining Convertible Notes [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term	5 months 26 days
Remaining Convertible Notes [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input term	10 months 9 days
Remaining Convertible Notes [Member] | Measurement Input, Exercise Price [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input | $ / shares	0.0016

Equity (Details Narrative)

Equity (Details Narrative) - USD ($)		3 Months Ended		12 Months Ended
	Jan. 03, 2023	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Aug. 09, 2022
Subsidiary, Sale of Stock [Line Items]
Aggregate authorized capital		4,505,000,000
Common stock, shares authorized		4,500,000,000		4,500,000,000
Common stock, par value		$ 0.001		$ 0.001
Preferred Stock, Shares Authorized		5,000,000		5,000,000
Common stock, shares issued		2,748,956,631		2,617,390,830
Common stock, shares outstanding		2,748,956,631		2,617,390,830
Preferred stock, shares issued		2		2	2
Preferred stock, shares outstanding		2		2
Common stock issued for investment in Private Placement		$ 130,086	$ 345,000
Common stock issued for salaries		20,000	29,999
Common stock issued for license			3,107,570
Common stock issued for conversion of convertible notes		$ 188,459	$ 228,365
Preferred stock, par value		$ 0.001		$ 0.001	$ 0.001
Convertible Notes Payable [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock issued for conversion of convertible notes, shares	4,054,054	46,259,344		64,139,744
Common stock issued for conversion of convertible notes	$ 15,000	$ 203,459		$ 1,313,772
Prepaid Fees [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock issued for prepaid fees, shares				11,000,000
Common stock issued for prepaid fees				$ 242,320
Salaries [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock issued for salaries, shares		4,081,632		4,812,259
Common stock issued for salaries		$ 20,000		$ 67,399
Consulting Services [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock issued for consulting services, shares	3,000,000	21,000,000		32,412,577
Common stock issued for consulting services	$ 18,000	$ 141,200		$ 691,520
License [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock issued for license, shares				149,402,390
Common stock issued for license				$ 3,107,570
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock issued for investment in Private Placement, shares		60,224,825		44,500,000
Common stock issued for investment in Private Placement		$ 130,086		$ 445,000

Subsequent events (Details Narr

Subsequent events (Details Narrative) - USD ($)											3 Months Ended		12 Months Ended
	May 10, 2023	May 10, 2023	May 03, 2023	May 03, 2023	Apr. 28, 2023	Apr. 24, 2023	Apr. 20, 2023	Apr. 06, 2023	Apr. 03, 2023	Jan. 03, 2023	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Subsequent Event [Line Items]
Common stock issued for conversion of convertible notes											$ 188,459	$ 228,365
Common stock issued for investment in Private Placement											$ 130,086	$ 345,000
Consulting Services [Member]
Subsequent Event [Line Items]
Common stock issued for consulting services, shares										3,000,000	21,000,000		32,412,577
Private Placement [Member]
Subsequent Event [Line Items]
Common stock issued for investment in Private Placement, shares											60,224,825		44,500,000
Common stock issued for investment in Private Placement											$ 130,086		$ 445,000
Convertible Notes Payable [Member]
Subsequent Event [Line Items]
Common stock issued for conversion of convertible notes, shares										4,054,054	46,259,344		64,139,744
Common stock issued for conversion of convertible notes										$ 15,000	$ 203,459		$ 1,313,772
Subsequent Event [Member] | Consulting Services [Member]
Subsequent Event [Line Items]
Common stock issued for consulting services, shares							25,000,000
Share issued price per share							$ 24
Subsequent Event [Member] | Private Placement [Member]
Subsequent Event [Line Items]
Common stock issued for investment in Private Placement, shares						89,639,965		40,959,979
Common stock issued for investment in Private Placement						$ 150,595		$ 75,366
Subsequent Event [Member] | Convertible Notes Payable [Member]
Subsequent Event [Line Items]
Common stock issued for conversion of convertible notes, shares	16,500,000	27,500,000	17,975,000	13,750,000	20,000,000				21,308,333
Common stock issued for conversion of convertible notes	$ 82,500	$ 110,000	$ 26,963	$ 27,500	$ 30,000				$ 31,962

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)		3 Months Ended
	Mar. 22, 2023 ft²	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Area of land | ft²	1,700
Lease contract term	60 months
Lease expiration date	Apr. 30, 2028
Payment for rent | $		$ 6,261	$ 6,261
Operating lease discount rate		5%